Entos Pharmaceuticals is focused on the development of next generation nucleit acid-based therapies using their proprietary Fusogenix drug delivery system. Fusogenix is a non-toxic lipid nanoparticle platform that utilizes a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells invivo. The technology is suitable for targeting extra-hepatic diseases and is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR